



## Announcement Summary

---

**Entity name**

BIO-GENE TECHNOLOGY LTD

**Announcement Type**

New announcement

**Date of this announcement**

Tuesday May 26, 2020

**The Proposed issue is:**

An offer of securities under a securities purchase plan

**Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan**

<b>ASX +Security Code</b>	<b>+Security Description</b>	<b>Maximum Number of +securities to be issued</b>
BGT	ORDINARY FULLY PAID	9,677,419

**+Record date**

Monday May 25, 2020

**Offer closing date**

Tuesday June 16, 2020

**+Issue date**

Monday June 22, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of +Entity**

BIO-GENE TECHNOLOGY LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

**1.2 Registered Number Type**

ABN

**Registration Number**

32071735950

**1.3 ASX issuer code**

BGT

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

Tuesday May 26, 2020

**1.6 The Proposed issue is:**

An offer of +securities under a +securities purchase plan



Part 4 - Details of proposed offer under securities purchase plan

---

Part 4A - Conditions

---

**4A.1 - Are any of the following approvals required for the offer of +securities under the +securities purchase plan issue to be unconditional?**

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

No

Part 4B - Offer details

---

**Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued**

**ASX +Security Code and Description**

BGT : ORDINARY FULLY PAID

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

Details of +securities proposed to be issued

---

**ASX +Security Code and Description**

BGT : ORDINARY FULLY PAID

**Maximum Number of +securities proposed to be issued**

9,677,419

**Minimum Number of +securities proposed to be offered to each individual +security holder**

6,451

**Maximum Number of +securities proposed to be offered to each individual +security holder**

193,548



<b>Minimum subscription \$ amount proposed to be offered to each individual security holder</b>	<b>Maximum subscription \$ amount proposed to be offered to each individual security holder</b>
AUD 1,000	AUD 30,000

**Purpose of the issue**

- ⌘ Continue and expand commercialisation discussions;
- ⌘ Accelerate registration enabling studies;
- ⌘ Enable additional research on product efficacy and MOA (mode of action); and
- ⌘ General working capital.

**Offer price details for retail security holders**

<b>Issue Currency</b>	<b>Offer Price per +security</b>	<b>Estimated or Actual?</b>
AUD - Australian Dollar	AUD 0.15500	<input checked="" type="checkbox"/> Actual

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

**Oversubscription & Scale back details**

**May a scale back be applied to this event?**

Yes

**Provide the scale back details**

If a scale back is necessary, it will be applied on a pro rata basis to all participants based on the size of their existing security holdings.

Part 4C - Timetable

**4C.1 Date of announcement of +security purchase plan**

Tuesday May 26, 2020

**4C.2 +Record date**

Monday May 25, 2020

**4C.3 Date on which offer documents will be made available to investors**

Wednesday May 27, 2020

**4C.4 Offer open date**

Wednesday May 27, 2020

**4C.5 Offer closing date**

Tuesday June 16, 2020



#### 4C.6 Announcement of results

Friday June 19, 2020

#### 4C.7 +Issue date

Monday June 22, 2020

### Part 4D - Listing Rule requirements

---

**4D.1 Does the offer under the +securities purchase plan meet the requirements of listing rule 7.2 exception 5 that:**

- the number of +securities to be issued is not greater than 30% of the number of fully paid +ordinary securities already on issue; and
- the issue price of the +securities is at least 80% of the +volume weighted average market price for +securities in that +class, calculated over the last 5 days on which sales in the +securities were recorded, either before the day on which the issue was announced or before the day on which the issue was made?

Yes

### Part 4E - Fees and expenses

---

**4E.1 Will there be a lead manager or broker to the proposed offer?**

Yes

**4E.1a Who is the lead manager/broker?**

Henslow Pty Ltd

**4E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?**

6% of any shortfall placed

**4E.2 Is the proposed offer to be underwritten?**

No

**4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?**

No

**4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer**

Not Applicable

### Part 4F - Further Information

---



**4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?**

No

**4F.2 Countries in which the entity has security holders who will not be eligible to accept the proposed offer**

China, Italy, Japan, Singapore, United Arab Emirates and USA

**4F.3 URL on the entity's website where investors can download information about the proposed offer**

<http://bio-gene.com.au/investors/asx-announcements/>

The information will be available on the website after the SPP Booklet has been mailed to shareholders which is expected to be by close of business AEST 27 May 2020

**4F.4 Any other information the entity wishes to provide about the proposed offer**

If there is a shortfall in acceptance it will be offered to sophisticated, professional or other exempt investors at the discretion of the Company